Get started
Author

Robert D. Little

Observed names: Little, R, R D Little, R Little, R. Little, R.D. Little, Robert D Little, Robert Little
Observed institutions: Northern Health, The Alfred Hospital, Northern Hospital, UNSW Sydney, St Vincent's Hospital Melbourne, Monash Health, Hospital Universitario Fundación Jiménez Díaz, Alfred Health, Monash University, Universidad Autónoma de Madrid
ORCID: 0000-0002-5314-6666
Observed ORCID: 0000-0002-5314-6666
OpenAlex ID: A5028588621
Compensatory anabolic signaling in the sarcopenia of experimental chronic arthritis
2017 · Robert D. Little, Iván Prieto-Potin, et al. · Scientific Reports · 45
PDF
Therapeutic Drug Monitoring of Subcutaneous Infliximab in Inflammatory Bowel Disease—Understanding Pharmacokinetics and Exposure Response Relationships in a New Era of Subcutaneous Biologics
2022 · Robert D. Little, Mark G. Ward, et al. · Journal of Clinical Medicine · 44
PDF
Pathogenesis and precision medicine for predicting response in inflammatory bowel disease: advances and future directions
2024 · Robert D Little, Thisun Jayawardana, et al. · eGastroenterology · 42
PDF
A virtual clinic increases anti‐TNF dose intensification success via a treat‐to‐target approach compared with standard outpatient care in Crohn’s disease
2020 · Ashish Srinivasan, Daniel R. van Langenberg, et al. · Alimentary Pharmacology & Therapeutics · 18
PDF
The Role of Low-Dose Oral Methotrexate in Increasing Anti-TNF Drug Levels and Reducing Immunogenicity in IBD
2023 · Kathryn Demase, Cassandra K. Monitto, et al. · Journal of Clinical Medicine · 15
PDF
Amoebic colitis: A case series of a recurring missed diagnosis
2020 · Joshua Haron Abasszade, Robert Little, et al. · JGH Open · 13
PDF
DXA in the assessment of subchondral bone mineral density in knee osteoarthritis—A semi-standardized protocol after systematic review
2015 · Alexandre Sepriano, Jorge A. Roman-Blas, et al. · Seminars in Arthritis and Rheumatism · 13
Therapeutic drug monitoring in inflammatory bowel disease: recent developments
2024 · Xavier Roblin, Robert D. Little, et al. · Expert Review of Gastroenterology & Hepatology · 12
Determinants of Short- and Long-Term Outcomes of an Australian Cohort of Patients Admitted with Alcoholic Hepatitis
2021 · Karl Vaz, Robert Little, et al. · Digestive Diseases and Sciences · 10
Have changing practices in salvage medical options affected colectomy rates in acute severe ulcerative colitis?
2023 · Nicholas Clark, Michael MacIsaac, et al. · Internal Medicine Journal · 8
PDF
De-escalation from Dose-Intensified Anti-TNF Therapy Is Successful in the Majority of IBD Patients at 12 Months
2021 · Robert D. Little, Isabel E. Chu, et al. · Digestive Diseases and Sciences · 8
Dietary Patterns and Fibre Intake Are Associated with Disease Activity in Australian Adults with Inflammatory Bowel Disease: An Exploratory Dietary Pattern Analysis
2024 · Denelle Cosier, Kelly Lambert, et al. · Nutrients · 6
PDF
Switching from Dose-Intensified intravenous to SubCutaneoUS infliximab in Inflammatory Bowel Disease (DISCUS-IBD): protocol for a multicentre randomised controlled trial
2024 · Robert D Little, Jo McKenzie, et al. · BMJ Open · 6
Adalimumab Drug Levels at Secondary Loss of Response Do Not Predict Response to Dose-intensification in Crohn’s Disease: A Retrospective, International Multicenter Study
2023 · Robert D Little, Adrian Swaine, et al. · Inflammatory Bowel Diseases · 5
Gut Microbiota Are More Strongly Associated With Impairments in Health-Related Quality of Life Than Disease Activity in Inflammatory Bowel Disease
2025 · Robert D. Little, Thisun C. Jayawardana, et al. · The American Journal of Gastroenterology · 4
P713 The introduction of an intestinal ultrasound service significantly reduces diagnostic endoscopy usage in an Inflammatory Bowel Disease service – The SCOPELESS Study
2024 · G Feng, R Little, et al. · Journal of Crohn s and Colitis · 2
PDF
Letter to the Editor: Predicting mortality after transjugular intrahepatic portosystemic shunt in older adult patients with cirrhosis—Does novelty supplant the standard?
2022 · Karl Vaz, Robert Little, et al. · Hepatology · 2
Can Subcutaneous Infliximab Replace Dose-Intensified Intravenous Administration in Inflammatory Bowel Disease?
2022 · Robert D. Little, Mark G. Ward, et al. · Clinical Gastroenterology and Hepatology · 2
Letter: the diagnostic and prognostic significance of liver histology in alcoholic hepatitis
2021 · Karl Vaz, Catriona McLean, et al. · Alimentary Pharmacology & Therapeutics · 2
PDF
Editorial: anti‐drug antibodies and the benefit of assay validation
2020 · Robert Little, Miles P. Sparrow · Alimentary Pharmacology & Therapeutics · 2
PDF
Comparison of Adalimumab Serum Drug Levels When Delivered by Pen Versus Syringe in Patients With Inflammatory Bowel Disease. An International, Multicentre Cohort Analysis
2019 · Robert D Little, Isabel E Chu, et al. · Journal of Crohn s and Colitis · 2
PDF
980 Randomised Controlled Trial of Continued Intravenous Versus Switching to Subcutaneous Infliximab in Inflammatory Bowel Disease: the Subcutaneous Infliximab Switch Study (siss).
2026 · John D. Chetwood, Diane Redmond, et al. · Gastroenterology · 1
Trends in Length of Stay, Steroid Use and Colectomy Rates in Patients Admitted with Acute Severe Ulcerative Colitis: The Impact of Accelerated and Intensified Infliximab Dosing
2026 · Ryan Bartlett, Mustafa Mohamedrashed, et al. · Digestive Diseases and Sciences · 1
P1344 Impaired health-related quality of life is associated with alterations in gut microbiota signatures in patients with Inflammatory Bowel Disease: baseline data from the Australian IBD Microbiome study
2025 · T Jayawardana, R D Little, et al. · Journal of Crohn s and Colitis · 1
Clinical features and outcomes of adult idiopathic megarectum
2023 · Kyle Wu, Robert D. Little, et al. · European Journal of Gastroenterology & Hepatology · 1
Works count: 55
Citation count: 268
H-index: 9
I10-index: 9
Year
Topic
Type